Michael Nohaile
Direktor/Vorstandsmitglied bei FULGENT GENETICS, INC.
Vermögen: 47 711 $ am 30.04.2024
Profil
Michael Nohaile is currently the Chief Executive Officer at Prellis Biologics, Inc. and an Independent Director at Fulgent Genetics, Inc. He is also the Chief Scientific Officer at Generate Biomedicines, Inc. Dr. Nohaile's former positions include Director at Genoptix, Inc., Senior VP-Strategy, Commercialization & Innovation at Amgen, Inc., General Manager-Molecular Diagnostics Business at Novartis Corp., and Partner at McKinsey & Co., Inc. Dr. Nohaile received his undergraduate degree from Massachusetts Institute of Technology and his doctorate from the University of California, Berkeley.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
FULGENT GENETICS, INC.
0,01% | 21.03.2024 | 2 382 ( 0,01% ) | 47 711 $ | 30.04.2024 |
Aktive Positionen von Michael Nohaile
Unternehmen | Position | Beginn |
---|---|---|
FULGENT GENETICS, INC. | Direktor/Vorstandsmitglied | 01.08.2022 |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Technik-/Wissenschafts-/F&E-Leiter | - |
Prellis Biologics, Inc.
Prellis Biologics, Inc. BiotechnologyHealth Technology Prellis Biologics, Inc. engages in building human tissues for drug development, and also develops human organs for transplantation. It offers vascularized tissue, bio and human organ printing. The firm's products include Organoid, Vascular Bundle, 3D Tissue Chip, Cell Seeding Matrix, Cell Adhesion Plus and Holograph-X Bioprinter. The company was founded by Noelle Huskey Mullin and Melanie Matheu in October 2016 and is headquartered in San Francisco, CA. | Vorstandsvorsitzender | 11.08.2022 |
Ehemalige bekannte Positionen von Michael Nohaile
Unternehmen | Position | Ende |
---|---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.11.2012 |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.01.2007 |
Genoptix, Inc.
Genoptix, Inc. Medical SpecialtiesHealth Technology Genoptix, Inc. provides specialized oncology diagnostics services. It offers a range of customizable clinical trial, custom assay development and companion diagnostics development services. The company was founded in 1999 by Tina S. Nova and is headquartered in Carlsbad, CA. | Direktor/Vorstandsmitglied | - |
AMGEN INC. | Corporate Officer/Principal | - |
Ausbildung von Michael Nohaile
University of California, Berkeley | Doctorate Degree |
Massachusetts Institute of Technology | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AMGEN INC. | Health Technology |
FULGENT GENETICS, INC. | Health Services |
Private Unternehmen | 5 |
---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Health Technology |
Prellis Biologics, Inc.
Prellis Biologics, Inc. BiotechnologyHealth Technology Prellis Biologics, Inc. engages in building human tissues for drug development, and also develops human organs for transplantation. It offers vascularized tissue, bio and human organ printing. The firm's products include Organoid, Vascular Bundle, 3D Tissue Chip, Cell Seeding Matrix, Cell Adhesion Plus and Holograph-X Bioprinter. The company was founded by Noelle Huskey Mullin and Melanie Matheu in October 2016 and is headquartered in San Francisco, CA. | Health Technology |
Genoptix, Inc.
Genoptix, Inc. Medical SpecialtiesHealth Technology Genoptix, Inc. provides specialized oncology diagnostics services. It offers a range of customizable clinical trial, custom assay development and companion diagnostics development services. The company was founded in 1999 by Tina S. Nova and is headquartered in Carlsbad, CA. | Health Technology |